These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35624169)

  • 41. [Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways].
    Crager SE
    Rev Panam Salud Publica; 2015 Jan; 37(1):59-68. PubMed ID: 25791189
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030.
    Sim SY; Watts E; Constenla D; Huang S; Brenzel L; Patenaude BN
    Value Health; 2021 Jan; 24(1):70-77. PubMed ID: 33431156
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia.
    Loganathan T; Ng CW; Lee WS; Hutubessy RCW; Verguet S; Jit M
    Health Policy Plan; 2018 Mar; 33(2):204-214. PubMed ID: 29228339
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmaceutical Reference Pricing: Does It Have a Future in the U.S.?
    Robinson JC
    Issue Brief (Commonw Fund); 2018 Sep; 2018():1-6. PubMed ID: 30199167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Children's Vaccine Initiative and vaccine supply: the role of the public sector.
    van Noort RB
    Vaccine; 1992; 10(13):909-10. PubMed ID: 1471410
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmaceutical Industry's Engagement in the Global Equitable Distribution of COVID-19 Vaccines: Corporate Social Responsibility of EUL Vaccine Developers.
    Sung M; Huang Y; Duan Y; Liu F; Jin Y; Zheng Z
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Attitudes Toward the Global Allocation of Chinese COVID-19 Vaccines: Cross-sectional Online Survey of Adults Living in China.
    Yu H; Du R; Wang M; Yu F; Yang J; Jiao L; Wang Z; Liu H; Wu P; Bärnighausen T; Xue L; Wang C; McMahon S; Geldsetzer P; Chen S
    JMIR Public Health Surveill; 2022 Jun; 8(6):e33484. PubMed ID: 35483084
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Variation in provider vaccine purchase prices and payer reimbursement.
    Freed GL; Cowan AE; Gregory S; Clark SJ
    Pediatrics; 2009 Dec; 124 Suppl 5():S459-65. PubMed ID: 19948577
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Casting off vaccine supply charity -- the pace quickens. CVI goal: quality vaccines for all children.
    CVI Forum; 1995 Oct; (10):9-13. PubMed ID: 12290725
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trends and Insights from Transportation Congestion Pricing Policy Research: A Bibliometric Analysis.
    Singichetti B; Dodd A; Conklin JL; Hassmiller Lich K; Sabounchi NS; Naumann RB
    Int J Environ Res Public Health; 2022 Jun; 19(12):. PubMed ID: 35742442
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trends in childhood vaccine purchase costs in the US public sector: 1996-2014.
    Chen W; Messonnier M; Zhou F
    Vaccine; 2016 Sep; 34(39):4706-4711. PubMed ID: 27522176
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vaccine pricing: how can we get it right?
    Jacobson SH
    Expert Rev Vaccines; 2012 Oct; 11(10):1163-5. PubMed ID: 23176647
    [No Abstract]   [Full Text] [Related]  

  • 55. Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014.
    Williams WW; Lu PJ; O'Halloran A; Kim DK; Grohskopf LA; Pilishvili T; Skoff TH; Nelson NP; Harpaz R; Markowitz LE; Rodriguez-Lainz A; Bridges CB;
    MMWR Surveill Summ; 2016 Feb; 65(1):1-36. PubMed ID: 26844596
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment.
    Patterson BJ; Myers K; Stewart A; Mange B; Hillson EM; Poulos C
    Expert Rev Vaccines; 2021 Jun; 20(6):729-741. PubMed ID: 33902368
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A systematic review of reference pricing: implications for US prescription drug spending.
    Lee JL; Fischer MA; Shrank WH; Polinski JM; Choudhry NK
    Am J Manag Care; 2012 Nov; 18(11):e429-37. PubMed ID: 23198752
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future.
    Pilkington V; Keestra SM; Hill A
    Front Public Health; 2022; 10():821117. PubMed ID: 35321196
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Communication about vaccine efficacy and COVID-19 vaccine choice: Evidence from a survey experiment in the United States.
    Kreps S; Kriner DL
    PLoS One; 2022; 17(3):e0265011. PubMed ID: 35353846
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improving global vaccine accessibility.
    Hill AB; Kilgore C; McGlynn M; Jones CH
    Curr Opin Biotechnol; 2016 Dec; 42():67-73. PubMed ID: 26994376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.